BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191210
DTEND;VALUE=DATE:20191212
DTSTAMP:20260515T041940
CREATED:20190909T102201Z
LAST-MODIFIED:20190909T123702Z
UID:22345-1575936000-1576108799@www.pharmajournalist.com
SUMMARY:BioFIT 2019
DESCRIPTION:EARLY-STAGE INNOVATIONS | ACADEMIA-INDUSTRY COLLABORATIONS | TECHNOLOGY TRANSFER | SEED INVESTMENT \nWith the highest attending rate of TTOs\, research institutes and academia together with big pharma\, emerging and small biotech\, diagnostics companies\, pre-seed / seed / Series A investors\, BioFIT is the leading partnering event in Europe for technology transfer\, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed\, seed and Series A investment in Life Sciences. \nWHY ATTEND BIOFIT? \nOut of 1\,000 BioFIT attendees\, 1\,000 deals have been generated. The breakdown in terms of nature of deals is the following: \n\n35% of collaborative research projects\n30% of licensing deals\n15% of equity investment deals\n20% of services deals\n\nEstimate based on the measurement of 2015 and 2016 delegates’ outcomes \n  \nKEY FIGURES: \n\n1\,300+ delegates\n800+ organisations\n35+ countries represented\n1\,000 deals generated in 2017\n\nINSIDE THE EVENT: \n\nA business convention with pre-qualified one-to-one meetings\n Identification of would-be CEOs\nConferences and roundtable discussions\nOral presentations of start-ups \, licensing opportunities stemming from academia \, service presentations\nAn exhibition area\nInformal networking evenings\n\nPlease check out the different participants’ lists of the previous editions\, as well as the list of this year’s edition >>here<<.\n2018 Final programme\n2019 Preliminary programme \nPlease feel free to widely share this document with your colleagues\, network\, partners… \nBE PART OF THE EVENT: \n\nRegister now\nBook your booth now\n\nWebsite: www.biofit-event.com\nTwitter: @BIOFIT_EVENT
URL:https://www.pharmajournalist.com/event/biofit-2019/
LOCATION:MARSEILLE CHANOT\, PALAIS DES CONGRÈS ET DES EXPOSITIONS Rond Point du Prado 13008 Marseille – FRANCE
ORGANIZER;CN="Eurasant%C3%A9":MAILTO:msatola@eurasante.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191210
DTEND;VALUE=DATE:20191213
DTSTAMP:20260515T041940
CREATED:20191101T123339Z
LAST-MODIFIED:20191101T124951Z
UID:23209-1575936000-1576195199@www.pharmajournalist.com
SUMMARY:Cell Therapy Analytical Development Summit
DESCRIPTION:The explosion in cell therapy development companies has fueled a need to develop well-characterized clinical products which has resulted in the call for robust and validated analytical assays now being louder and more important than ever before. \nThe inaugural Cell Therapy Analytical Development Summit brings you the leaders in CMC\, analytics and process development to create standardized and automated analytical techniques and technologies for improved therapeutic characterization at scale. \nJoin over 100 of the world’s experts as we discuss how to navigate a murky regulatory landscape\, robustly validate assays and advance the characterization of CAR-T and TCR cell therapy analytics to ensure safe\, consistent and quality cell therapy products. \n \nGet involved this December to: \n\nAddress the need to fully understand the mechanism of action of a cell therapy to develop representative potency assays\nAssess methods to develop functional assays suitable for routine and timely testing to overcome operational constraints\nExplore ways to develop non-destructive and non-invasive in-line analytics\nDiscuss current techniques being developed to standardize flow cytometry and explores ways to overcome batch effects\nHighlight sources of variability in cell counting measurement such as environmental\, procedural\, analytical and instrumental\, and techniques to minimize variability\n\nWhy do experts attend our cell therapy summits? \n“Moments where we can come together with passionate individuals and companies who are focused on advancing cancer care are inspiring\, and the Cell Therapy Summit is no different. We are energized by the discussions about cell therapy and its potential applications for bringing new therapies to patients in need.”\n– Novartis \n“This is a best in class and top summit in the cell therapy area which is an invaluable asset to both industries and academia.”\n– University of Pennsylvania \nJoin us to ensure safe\, consistent and quality cell therapy development with novel\, scalable and automated analytical development assays. \nTo know more about Cell Therapy Analytical Development Summit click here
URL:https://www.pharmajournalist.com/event/cell-therapy-analytical-development-summit/
LOCATION:Revere Hotel Boston Common  200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR